{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=19", "query": { "condition": "EGFR", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 838, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T17:59:23.066Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03647488", "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-26", "completion_date": "2020-09-07", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 1, "location_summary": "Fayetteville, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647488" }, { "nct_id": "NCT00861627", "title": "Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small Cell Lung" ], "interventions": [ { "name": "REOLYSIN®", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2009-03", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2015-12-02", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Columbus, Ohio", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861627" }, { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" }, { "nct_id": "NCT00577707", "title": "Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2007-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577707" }, { "nct_id": "NCT07659795", "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "VS-7375", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "panitumumab", "type": "DRUG" }, { "name": "Cetuximab + mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-07-28", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Coral Springs, Florida + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07659795" }, { "nct_id": "NCT06709521", "title": "Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bacterial Infection" ], "interventions": [ { "name": "Iohexol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2025-02-12", "completion_date": "2026-07-02", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 10, "location_summary": "Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 6 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06709521" }, { "nct_id": "NCT05498389", "title": "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "EGFR Mutation-Related Tumors" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2023-06", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 2, "location_summary": "Orange, California • Boston, Massachusetts", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05498389" }, { "nct_id": "NCT03511560", "title": "Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant Rejection", "Kidney Transplant Failure and Rejection" ], "interventions": [ { "name": "Tacrolimus Extended Release Oral Tablet", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2018-07-26", "completion_date": "2021-07-17", "has_results": true, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511560" }, { "nct_id": "NCT00198159", "title": "A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Germ Cell Tumors Expressing EGRF" ], "interventions": [ { "name": "ZD1839 Iressa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 21, "start_date": "2002-09", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2014-09-19", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00198159" }, { "nct_id": "NCT02573324", "title": "A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Depatuxizumab mafodotin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Placebo for ABT-414", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 691, "start_date": "2015-01-04", "completion_date": "2022-04-04", "has_results": true, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-11-08T17:59:23.066Z", "location_count": 68, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573324" } ] }